Evidence analysisNovember 11, 2026Health & Science

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 31, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Flixabi is a biosimilar medicine containing infliximab, a monoclonal antibody targeting tumour necrosis factor-alpha (TNF-alpha), an inflammatory protein elevated in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. It was authorized in the European Union on 26 May 2016 based on evidence demonstrating comparable quality, safety, and efficacy to the reference medicine Remicade.

Flixabi is typically prescribed when other treatments have failed or are inappropriate. It is administered intravenously, with dosage and infusion schedules tailored to the specific disease and patient response. The European Medicines Agency (EMA) mandates specialist oversight for initiation and continued use, including monitoring for infusion-related reactions.

What the source claims

  • Flixabi effectively reduces symptoms in diseases such as rheumatoid arthritis and inflammatory bowel diseases, with clinical studies showing similar outcomes to Remicade; for example, 64% of patients achieved at least a 20% improvement in arthritis symptoms after 30 weeks.
  • The common side effects include viral infections, headaches, respiratory infections, nausea, abdominal pain, and infusion-related adverse events.
  • Flixabi must not be used in patients with allergies to infliximab or related ingredients, active tuberculosis, severe infections, or moderate to severe heart failure.
  • A risk management plan accompanies Flixabi to guide safe usage, including educational materials for prescribers and alert cards for patients, particularly emphasizing infection risks in pediatric patients.
  • The EMA’s Committee for Medicinal Products for Human Use (CHMP) concluded the benefits of Flixabi outweigh the identified risks, granting marketing authorization across the EU.

What may be missing from the usual framing

The EMA summary presents Flixabi primarily through regulatory and clinical study data demonstrating biosimilarity and safety in controlled settings. It does not discuss the broader context of biosimilar market dynamics, such as pricing competition or patent expirations that often drive the introduction of biosimilars.

Additionally, the summary focuses on common adverse effects but does not elaborate in detail about rare or long-term immunogenicity concerns which sometimes affect biologic therapies. Information on patient-reported outcomes, quality of life measures, or head-to-head comparisons with other biologics beyond Remicade is not covered.

Economic factors, access considerations, and potential variation in efficacy or side effects in diverse patient populations may also be insufficiently explored within this regulatory document.

Competing evidence or uncertainty

While the EPAR for Flixabi provides evidence from clinical trials demonstrating equivalence to Remicade, questions remain common for biosimilars about interchangeability—whether patients can be safely switched from an original biologic to a biosimilar without loss of efficacy or increased risks.

Post-marketing pharmacovigilance data, which could reveal rarer side effects or long-term safety signals, is not available within this summary and would be necessary for a more complete picture.

It is also unclear how Flixabi’s efficacy compares to other TNF-alpha inhibitors or alternative therapies in real-world clinical practice, which may differ from trial environments.

Why it matters

Biosimilar drugs like Flixabi potentially provide cost-effective alternatives to expensive originator biologics, potentially increasing patient access to treatments for chronic immune-mediated inflammatory diseases. Understanding their safety and efficacy is critical for clinicians, patients, and healthcare systems making treatment decisions.

Given the chronic nature of the indications treated, safety monitoring and education on infection risks, especially in pediatric use, are vital to mitigate lifelong health impacts.

Regulatory thoroughness, transparency, and ongoing data collection help build confidence in biosimilars, influencing prescribing practices, reimbursement, and patient outcomes.

What to verify next

  • Review independent post-marketing surveillance studies and real-world evidence concerning Flixabi’s long-term safety, efficacy, and immunogenicity.
  • Examine comparative studies or meta-analyses including multiple TNF-alpha inhibitors and biosimilars to contextualize Flixabi’s clinical performance.
  • Investigate patient and clinician experiences with switching from originator biologics to Flixabi, focusing on safety and efficacy retention.
  • Assess health economic evaluations comparing Flixabi with Remicade and other biologics, exploring access and affordability impacts in different healthcare systems.
  • Monitor updates or communications from EMA regarding any newly identified risks or revised recommendations.

Readers are encouraged to consult the original EMA European public assessment report (EPAR) and associated regulatory documents for detailed official information and to verify claims with additional independent sources.

Source & verification

Primary source: What's new · November 11, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…